YH004 4-1BB

YH004 is a novel humanized antibody targeting 4-1BB, a member of the tumor necrosis factor receptor superfamily, on the surface of immune cells, using a unique IgG1 subtype. 4-1BB is mainly expressed in T cells, DC cells, monocytes, B cells, mast cells, NK cells and neutrophils. As a 4-1BB agonist, YH004 can induce immune cell proliferation and cytokine expression to activate the body’s immune response. In vivo preclinical experiments in mice showed that the single-drug and combined drug efficacies of YH004 were significantly better than those of the control. A large number of preclinical and clinical data have demonstrated the great potential of targeting 4-1BB for cancer immunotherapy, but the hepatotoxicity caused by 4-1BB agonists has hindered its further clinical development. In vitro functional analysis of YH004 showed that its binding affinity to human and monkey 4-1BB was equivalent, and no hepatotoxicity of YH004 was observed in in vivo toxicity tests of cynomolgous monkeys. YH004 is in the stage of preclinical safety evaluation and CMC development.

Back to top